Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy

• Published in: Anticancer research Vol. 42; no. 2; pp. 1091 - 1097
• Main Authors: Shibata, Naoki, Kawakami, Kazuyoshi, Hisanori, Shimizu, Kobayashi, Kazuo, Yunokawa, Mayu, Kanao, Hiroyuki, Taki, Iori, Murase, Remi, Kamei, Daisuke, Yamaguchi, Masakazu
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.02.2022
• Subjects: Adult; Aged; Cancer; Carboplatin; Carboplatin - therapeutic use; Carcinoma, Ovarian Epithelial - drug therapy; Carcinoma, Ovarian Epithelial - epidemiology; Desensitization; Desensitization, Immunologic - methods; Drug Eruptions - drug therapy; Drug Eruptions - epidemiology; Drug Hypersensitivity - drug therapy; Drug Hypersensitivity - epidemiology; Erythema; Female; Humans; Hypersensitivity; Japan - epidemiology; Middle Aged; Organs; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - epidemiology; Patients; Retrospective Studies; Therapy; Toxicity; Treatment Outcome; Japan; arms; erythema; Carboplatin desensitization; ovarian cancer; hypersensitivity reactions; criteria for discontinuation
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.15571

Carboplatin is a key drug in the treatment of ovarian cancer, but hypersensitivity reactions (HSRs) may occur with repeated use. Thirty-seven ovarian cancer patients treated with carboplatin desensitization therapy were reviewed retrospectively. The treatment completion rate and toxicity were examined. The carboplatin desensitization completion rate was 86.5%. Toxicity was Grade 0, 1, 2, and 3 in 17, 5, 10, and 5 patients, respectively. Erythema was the most frequent toxicity (36.8%), most commonly affecting the arm (23.5%). Furthermore, all HSRs were classified into: skin, respiratory, digestive, circulatory, and neurological. The completion rate of desensitization was significantly lower in patients with two or more target organs affected (p<0.001). The main symptoms of HSRs, the most common sites of HSRs, and the criteria for discontinuing desensitization therapy identified in this study are useful information for the safe implementation of carboplatin desensitization therapy.